All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Highlights of the Lymphoma Hub Satellite Symposium
Bookmark this article
At this year’s European School of Haematology (ESH) ‘2nd How to Diagnose and Treat: Lymphoma’ conference, the Lymphoma Hub hosted a virtual Satellite Symposium. Here, the Lymphoma Hub Chair, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, discussed the highlights from the symposium.
Highlights of the Lymphoma Hub Satellite Symposium
The symposium brought together a panel of international experts to discuss the management and treatment of patients with relapsed/refractory (R/R) lymphoma. During the symposium, Kieron Dunleavy and Marie José Kersten discussed the progress being made in the field of R/R diffuse large B-cell lymphoma (DLBCL), while Astrid Pavlovsky and Francesc Bosch discussed how they would treat a patient with R/R chronic lymphocytic leukemia (CLL).
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox